Robust Earnings Growth

Completion of GSK Manufacturing Facility Acquisition in Maryland, U.S.

With its expanding production capacity and stable growth trajectory, the share price of Samsung Biologics is on the rise. The company has also demonstrated strong efforts to secure additional growth drivers, as seen in its recent completion of the acquisition of manufacturing facilities in Maryland, United States.

[Market Focus] Samsung Biologics Rises Over 5% on Strong Earnings and U.S. Facility Acquisition View original image

As of 9:37 a.m. on April 2, Samsung Biologics was trading at 161,000 won, up 5.03% from the previous trading day.


On this day, Yuanta Securities maintained its “Buy” investment rating and a target price of 2.1 million won for Samsung Biologics. The brokerage projected first-quarter 2026 sales at 1.2612 trillion won (up 26.2% year-on-year) and operating profit at 591.5 billion won (up 37.6% year-on-year). Hyunsoo Ha, a researcher at Yuanta Securities, analyzed, “The recognition of deferred sales from fourth-quarter 2025 production and the full operation of Plants 1 through 4 will drive robust earnings growth.”


The company’s expansion of production capacity is also progressing smoothly. Sales recognition from the fifth plant began this year, and it is expected to make a substantial contribution to results starting next year. Researcher Ha stated, “The company plans to expand to Plants 6 through 8 by 2032, with groundbreaking for Plant 6 anticipated within this year. In the newly secured Third Bio Campus, Samsung Biologics will invest in next-generation modality CDMO (Contract Development and Manufacturing Organization) facilities, such as Antibody Drug Conjugates (ADC) and Cell and Gene Therapy (CGT).”



The recent completion of a U.S. manufacturing base is expected to serve as an additional growth engine. On March 31, Samsung Biologics finalized the acquisition of a GSK manufacturing facility in Maryland, United States. The final acquisition price was approximately 350 million dollars (around 410 billion won), and the facility has a production capacity of about 60,000 liters. Researcher Ha added, “Production will begin in the second quarter through employment succession, with sales recognition possible from 2030. There is also the possibility of an upward revision to the company’s annual sales growth guidance of 15–20% presented at the start of the year.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing